<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562494</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1105</org_study_id>
    <nct_id>NCT03562494</nct_id>
  </id_info>
  <brief_title>VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)</brief_title>
  <official_title>A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Voyager Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02
      in Patients with Parkinson's Disease with Motor Fluctuations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Sham Surgery Controlled, Double-blind, Multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ON time without troublesome dyskinesia as recorded by participant in Parkinson's Disease (PD) diary</measure>
    <time_frame>Baseline to Day 360</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III score in the OFF state</measure>
    <time_frame>Baseline to Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MDS-UPDRS II score</measure>
    <time_frame>Baseline to Day 360</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcome measured by treatment emergent adverse events (TEAEs), serious adverse events (SAEs), changes in vital signs and clinical laboratory analysis, and immunogenicity</measure>
    <time_frame>Baseline to Day 360</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>VY-AADC02 (NBIb-1817)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham (Placebo) Surgery</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham surgical procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VY-AADC02</intervention_name>
    <description>Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain</description>
    <arm_group_label>VY-AADC02 (NBIb-1817)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham (Placebo) Surgery</intervention_name>
    <description>Bilateral partial burr/twist holes without dura penetration</description>
    <arm_group_label>Sham (Placebo) Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Males and females, 40 to 75 years of age (inclusive)

          2. Diagnosis of PD, consistent with United Kingdom Brain Bank Criteria

          3. Motor responsiveness to dopaminergic therapy, demonstrated by improvement in MDS-UPDRS
             III score

          4. Disease duration from diagnosis of ≥4 years

          5. An average of ≥3 hours of OFF time (ie, periods of insufficient control of motor PD
             symptoms) per day over 3 consecutive days as confirmed by the PD Diary

          6. A stable, optimal regimen of Parkinson's medications including levodopa for at least
             weeks prior to screening evaluation. Participants must have a minimum duration of
             levodopa treatment of ≥1 year

          7. In the judgment of the Investigator, stable Parkinson's features and symptoms for at
             least 4 weeks prior to screening evaluation

          8. Agrees to defer any elective neurological surgery, including deep brain stimulation or
             ablation procedure for PD, levodopa or apomorphine infusion, or the addition of new
             dopaminergic formulations until after the study is completed, if medically appropriate

          9. Ability to travel to study visits

        Key Exclusion Criteria:

          1. Atypical or secondary parkinsonism, including but not limited to symptoms believed to
             be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological
             disease, or to drugs, chemicals, or toxins, as determined by the Investigator

          2. MoCA score &lt;26

          3. New or unstable psychiatric conditions (psychosis, depression) within 1 year of
             screening

          4. Brain imaging abnormalities in the striatum or other regions that would substantially
             increase risk of surgery

          5. Contraindication to MRI and/or gadolinium-based contrast agents

          6. Prior brain surgery, infusion therapies or planned treatments that could complicate
             the study procedure or negatively impact study evaluations as determined from
             participant interview, screening MRI, or medical records

          7. History of malignancy other than treated carcinoma in situ within 3 years of screening
             evaluation

          8. Prior gene transfer, current treatment with any investigational agent (drug or device)
             within 2 months of screening evaluation, or participation or plans to participate in
             another research study

          9. Severe, biphasic and/or uncontrolled dyskinesia

         10. Disabling or uncontrolled impulse control disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Liang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurocrocrine Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Chen</last_name>
    <phone>858-617-7744</phone>
    <email>cechen@neurocrine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan State University Department of Neurology</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic-Center for Neurological Restoration</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Clinical Trials Management Office</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Philadelphia, Dept of Neurology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://restore1study.com/</url>
    <description>RESTORE-1 Study Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease (PD)</keyword>
  <keyword>Aromatic L-Amino Acid Decarboxylase</keyword>
  <keyword>AADC</keyword>
  <keyword>AAV</keyword>
  <keyword>VY-AADC02</keyword>
  <keyword>AAV2-hAADC</keyword>
  <keyword>DDC</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>NBIb-1817</keyword>
  <keyword>Motor Fluctuations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

